The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of CA27.29 trend during adjuvant chemotherapy and until 2 years thereafter in patients with primary breast cancer.
B. K. Rack
Honoraria - Novartis; Sanofi
Other Remuneration - AstraZeneca; Lilly; Novartis; Sanofi
P. G. M. Hepp
No relevant relationships to disclose
U. Andergassen
No relevant relationships to disclose
J. K. Neugebauer
No relevant relationships to disclose
J. Salmen
No relevant relationships to disclose
G. Heinrich
No relevant relationships to disclose
J. Schreier
No relevant relationships to disclose
A. Hoenig
No relevant relationships to disclose
D. Finas
Honoraria - Sanofi
T. Zwingers
No relevant relationships to disclose
R. Kreienberg
No relevant relationships to disclose
M. W. Beckmann
Consultant or Advisory Role - AstraZeneca; Chugai Pharma; Lilly; Novartis; Sanofi
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Novartis; Sanofi
W. Lichtenegger
No relevant relationships to disclose
H. L. Sommer
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Novartis; Sanofi
K. Friese
No relevant relationships to disclose
W. Janni
Honoraria - AstraZeneca; Novartis; Sanofi
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Sanofi